Direct imaging of gemcitabine delivery in pancreatic ductal adenocarcinoma (PDAC) using CEST MRI
Yuguo Li 1,2 , Kannie W.Y. Chan 1,2 , Theodore Ewachiw 3 , Michael T McMahon 1,2 , Peter C.M. Van Zijl 1,2 , Zeshaan Rasheed 3 , and Guanshu Liu 1,2
F.M. Kirby Research Center for Functional
Brain Imaging, Kennedy Krieger Institute, Baltimore, MD,
of Radiology, Johns Hopkins University, Baltimore, MD,
of Oncology, Johns Hopkins University, Baltimore, MD,
One formidable challenge in treating advanced pancreatic
ductal adenocarcinoma (PDAC) is the highly heterogeneous
vascular barriers that hinder efficacious drug delivery.
Here, we propose a new approach to monitor delivery
directly using the inherent Chemical Exchange Saturation
Transfer (CEST) MRI signal carried by the drug. Our
results first showed that gemcitabine, the first-line
treatment for PDAC, could be readily detected by CEST
MRI via its exchangeable amino (2.3 ppm) and hydroxyl
(1.0 ppm) protons. We conclude that direct CEST MR
imaging of the uptake and distribution of gemcitabine in
PDAC tumors can be accomplished without the use of
additional imaging agents.
This abstract and the presentation materials are available to members only;
a login is required.